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Resumen
La osteoartritis (OA) es una enfermedad degenerativa,cuyo 
tratamiento convencional incluye medicamentos, fisioterapia 
o prótesis. Las células madre con Plasma Rico en Plaquetas y 
factores de crecimiento son una opción que promete controlar 
los síntomas, mejorar la función y regenerar el cartílago; 
sin embargo, no se han especificado muchos detalles del 
tratamiento, como el tipo y la cantidad de células madre que se 
deben aplicar para obtener mejores resultados. En este estudio 
buscamos comparar la efectividad, la seguridad y los costos 
de dos dosis (1X107vs 3X107) de células madre derivadas de 
tejido adiposo (ADSC), aplicadas por vía intraarticular.
Diez pacientes, con OA de rodilla grados II y III, fueron 
aleatorizados para recibir 10 (n = 5) o 30 millones (n = 5) 
de ADSC autólogos. Al inicio y 6 a 10 meses después de la 
inyección, se evaluaron de acuerdo con los criterios clínicos 
(evaluación médica, escala WOMAC, calidad de vida) y 
paraclínicos (artroscopia, resonancia, biopsia).
En términos de efectividad y seguridad no se observaron 
diferencias entre los dos grupos de dosificación, ya que 
todos los pacientes tuvieron una mejoría de acuerdo con 
los criterios médicos y la escala WOMAC (P = 0,001); en 
el control artroscópico, 7 pacientes tuvieron una respuesta 
“buena / muy buena”, 1 “neutral” y 2 abandonaron el control; 
Las biopsias confirman la regeneración articular, aunque no 
hubo diferencias en las resonancias magnéticas anteriores y 
posteriores.
En la osteoartritis de rodilla, la aplicación de 10 o 30 millones 
de ADSC fue igualmente efectiva y segura; sin embargo, el 
protocolo con 10 millones de células no requiere expansión in 
vitro, requiere menos tiempo, es más simple y tiene un costo 
menor. Este estudio muestra una buena razón para realizar 
ensayos clínicos aleatorios para obtener evidencia de mayor 
calidad.
Palabras clave: factores de crecimiento, osteoartritis, 
calidad de vida, medicina regenerativa, células madre.
Stem cell doses in knee osteoarthritis
Abstract
Osteoarthritis (OA) is a degenerative disease where 
conventional treatment includes drugs, physiotherapy, or 
prostheses. Stem cells and growth factors are a promising 
option in controlling symptoms, functional improvement and 
cartilage regeneration; however, many treatment details have 
not been specified, such as type and number of stem cells that 
should be applied to obtain optimal results. In this study we 
sought to compare effectiveness, safety and costs of two doses 
(1X107vs 3X107) of adipose tissue derived stem cells (ADSC), 
applied intra-articularly.
Ten patients, with knee OA grades II and III, were randomized 
to receive 10 (n=5) or 30 million (n=5) of autologous ADSCs. 
At baseline and 6 to 10 months after injection, they were 
evaluated according to clinical (medical evaluation, WOMAC 
scale, quality of life) and paraclinical criteria (arthroscopy, 
resonance, biopsy). 
In terms of effectiveness and safety there were no differences 
observed among the two dosage groups since all patients had 
improvement according to medical criteria and the WOMAC 
scale (P=0,001); in the arthroscopic control, 7 patients had 
“good/very good” response, 1 “neutral” and 2 forwent control; 
biopsies confirm joint regeneration, although there were no 
differences in the before and after magnetic resonances. 
In knee osteoarthritis, the application of 10 or 30 million 
ADSCs was equally effective and safe; however, the protocol 
with 10 million cells does not require in vitro expansion, 
requires less time, is simpler and has a lower cost. This study 
shows good reason to undertake randomized clinical trials to 
gain higher quality evidence. 
Key words: growth factors, osteoarthritis, quality of life, 
regenerative medicine, stem cells.
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Introduction
As the life expectancy of the population increases, diseases 
related to aging increase and many of which are becoming 
public health problems. This is the case of osteoarthritis 
(OA), a disease characterized by degeneration of the articular 
cartilage, alteration of the properties of the subchondral 
bone, inflammation of the synovial membrane, ligament 
degeneration and hypertrophy of the joint capsule (1,2). OA is 
the most common arthritis among adults and causes significant 
deterioration of the quality of life in people over the age of 65, 
especially for joint pain and disability (3). The main factors 
associated with OA are age, obesity, female gender and the 
genetic component (4).
The function of normal joint tissue depends on the relationship 
between the synovial membrane, the articular cartilage and 
the subchondral bone. Articular cartilage receives its nutrition 
by diffusing nutrients from the synovial fluid, through the 
extracellular matrix, whose components give the mechanical 
properties to the cartilage and facilitate joint lubrication 
(5). With natural tissue regeneration, growth inducers are 
released by the platelets, whose function is to stimulate tissue 
proliferation from the stem cells resident in the affected tissue; 
these factors also inhibit apoptosis and fibrosis, so that in most 
cases they induce normal tissue regeneration (6). Among the 
growth factors that have important chondrogenic activity, we 
can mention transforming growth factor-beta (TGF-beta), 
fibroblast growth factor (FGF) and insulin-like growth factor 
(IGF) (7).
The central pathological characteristic of OA is the loss 
of articular cartilage and the involvement of other joint 
components. It is divided into two categories: primary (to 
which efforts are directed, since it is the one with the highest 
incidence) results from biomechanical abnormalities or 
genetic predisposition; secondary is associated with metabolic, 
systemic or traumatic disorders, which alter the distribution 
of loads on the affected joint (8). Articular cartilage has poor 
repair capacity, mainly due to lack of vascularization and 
shortage of stem cells, so a focal lesion of the cartilage can 
be extended without there being any way to control it by 
conventional methods; additionally, it is possible that the little 
tissue that can regenerate does not have the same biochemical 
and biomechanical properties of the native cartilage (7,9).
These changes can be evidenced radiologically and they are 
based on the classification of knee osteoarthritis according to the 
scale of Kellgren and Lawrence: grade 1, doubtful narrowing 
of the joint space and possible osteophytosis; mild grade 2, 
possible narrowing of the joint space and osteophytosis; 
moderate grade 3, narrowing of the joint space and multiple 
moderate osteophytosis, mild sclerosis and possible deformity 
of the ends of the bones; severe grade 4, marked narrowing of 
the joint space, abundant osteophytosis, severe sclerosis and 
deformity of the ends of the bones, in addition to the clinical 
manifestation of knee pain, bone crepitus to active movements 
and morning stiffness.
The conventional treatment of OA, based on symptomatic 
medication and physiotherapy, shows only modest clinical 
benefits, therefore a good number of patients end up as 
candidates for joint replacement. Even so, 15 to 20% of patients 
are dissatisfied with surgery due to functional limitation, and 
20 to 30% continue with pain, which presents a serious concern 
since pain is the chief complaint of patients requesting surgery 
(3); therefore, all attention must be paid to the search for new 
alternatives for OA treatment.
Some cartilage repair techniques, such as abrasive 
chondroplasty, subchondral perforation and microfractures, 
seek to stimulate the migration of stem cells from the 
bone marrow to the damaged area and their subsequent 
differentiation into chondrocytes. Unfortunately, the tissue 
regenerated in this way does not possess the biological or 
biomechanical properties of the native cartilage, so it quickly 
degenerates. Regenerative medicine now emerges as a new 
therapeutic paradigm with the potential to regenerate damaged 
tissues and cure conditions that have been difficult to manage 
or have low level of response to traditional treatments (9).
Stem cells can be isolated from any tissue of the body and 
at any time of life, but among the different types of stem 
cells there are sufficiently important differences in terms of 
the requirements for obtaining them, yield in number of cells 
per gram of tissue, conditions of culture, vitality and potential 
for differentiation, among others (10,11). Stem cells derived 
from adipose tissue (ADSC) have turned out to be an attractive 
alternative for clinical use, not only for their relative ease 
of recovery, isolation and in vitro expansion, but because, 
compared to other cells, they have greater capacity for 
proliferation, in the laboratory they can be subjected to more 
passages without showing signs of senescence, maintaining 
their potential for differentiation and a stable phenotype, 
even after long periods of cultivation; they seem to be better 
for allogeneic transplantation than those of bone marrow. 
Finally, the patient’s age has less effect on their vitality 
and this is still shown in elderly patients with osteoporosis 
(12,13). In the specific case of the treatment of OA, ADSCs 
have shown high chondrogenic potential and low tendency 
towards osteogenic differentiation, with cartilage production 
of normal macroscopic characteristics and good integration 
with the subchondral bone (9,14). All these well-documented 
biological properties explain the rapid increase in preclinical 
and clinical studies with ADSCs in the treatment of a wide 
range of diseases, among which knee OA has received special 
attention. Indeed, several studies report that the injection of 
intraarticular stem cells result in clear recovery of cartilage 
and clinical parameters (pain and functional limitation), 
imaging, arthroscopy and quality of life (15-17); the addition 
of growth factors is done to stimulate cell proliferation and 
differentiation and generate an adequate extracellular matrix 
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to stimulate cartilage development (9). However, it should also 
be noted that concerns still persist regarding the source and 
manipulation of the stem cells to be used, the pharmaceutical 
forms to be administered, the administration routes and the 
optimal dosage regimen; on the other hand, some experts 
consider that, even though there is good confidence in safety, 
it is necessary to accumulate more evidence regarding the 
effectiveness of its application in humans (18).
In this trial, we proposed to evaluate the effectiveness, safety, 
and costs of two ADSC dose regimens administered intra-
articularly in patients with knee OA.
Materials and methods
Legal aspects. This pilot study was approved from a technical 
and scientific point of view by the respective academic 
instances of the Technological University of Pereira, and from 
the ethical point of view of the Bioethics Committee of the same 
university. Informed consent form was filled out and signed in 
accordance with Resolution 008430 of 1993 of the Ministry of 
Health of Colombia, in the category of “investigation with risk 
greater than the minimum”.
Patients and medical assessment. The study included 10 
patients over 40 years of age, both sexes, assessed by the 
specialist in Orthopedics and Traumatology, with OA grade 
II or III diagnosis (Kellgren-Lawrence classification), 
confirmed according to the criteria of the American College 
of Rheumatology (Altman 1986) by means of radiological, 
arthroscopic and magnetic resonance studies. The exclusion 
criteria were cerebral trauma, autoimmune disease, cognitive 
deficit or severe psychiatric illness (dementia or psychosis) 
that compromised the ability to sign the consent, hemorrhagic 
syndrome or coagulation disorder, active infection, 
immunological disorder, current consumption of NSAIDs or 
glucocorticoids, pregnancy or lactation. 
Process. Each volunteer filled out the information gathering 
document of the study and the following instruments were 
applied: i) The WOMAC scale (Western Ontario and Mc 
Master Universities Osteoarthritis Index), which is validated to 
determine the clinical response in patients with knee OA (19). 
This scale has been designed to measure symptomatology and 
physical disability of patients with knee osteoarthrosis, among 
others; contains 24 items, each with five levels, grouped into 
three domains: pain (0-20 points), rigidity (0-8 points) and 
functional disability (0-68). To present the results the scores of 
the three domains are added together and the total is multiplied 
by 100/96; thus, a value between 0 (the best) and 100 (the 
worst) is obtained. ii) The World Health Organization Quality 
of Life instrument, abbreviated version (WHOQoL-BREF), 
which estimates the quality of life in four areas: health and 
physical, psychological, social and environmental conditions 
(20). 
Patients were randomly assigned to the application of 10 
million stem cells directly isolated from adipose tissue, 
or 30 million of the same cells, cultured for two weeks. 
Subsequently, conventional magnetic resonances for knee OA 
were requested, without special recommendations, because 
the purpose was to determine its usefulness in this pathology. 
Finally, under spinal or general anesthesia, laparoscopies were 
performed and biopsies taken.
Obtaining the fat. In sterile conditions and in the same 
surgical act of arthroscopy, by means of a small incision in 
the abdominal wall, the doctor obtained by mini liposuction 
about 100 cc of adipose tissue. The sample was immediately 
transferred to the CeMaB/UTP Regenerative Medicine 
Laboratory.
Stem cells isolation and preparation. The lipoaspirate sample 
was subjected to the process of isolation and preparation 
of stem cells under sterile conditions with the Unistation 
(Neogenesis) and the closed system Unistation Adipose 
Stem Cell Isolation Device, by the procedure described by 
Yoshimura et al (21), which is endorsed by the International 
Society for Cell Therapy: the lipoaspirate sample is washed to 
remove erythrocytes and then 0.1% type I collagenase (Sigma, 
USA) is added and incubated at 37°C in the Unistation 
equipment with constant agitation for 30 min. The bottom layer 
is removed, transferred to a new 50 mL syringe containing 
HBSS (Gibco, USA) and centrifuged at Unistation at 1500 
rpm for 10 min. After the neutralization of the enzymes, the 
released elements are separated from the mature adipocytes 
by differential centrifugation; the mixture is centrifuged at 
1,500 rpm for 10 min to then remove the supernatant (22). To 
the patients whom 10 million ADSCs were applied, the pellet 
of the stromal vascular fraction containing the concentrated 
stem cells was reconstituted in a volume of 6 ml of plasma 
rich in growth factors, while the patients who were applied 30 
million ADSC, these cells were first cultivated until achieving 
the required concentration, at approximately two weeks.
Obtaining autologous platelet growth factors. Platelet rich 
plasma (PRP) was obtained using the Neogenesis PRP kit in 
the Unistation kit, for which 20 ml of blood was taken from the 
patient, with sodium citrate as an anticoagulant, in a syringe 
of the PRP Neogenesis kit, and centrifuged to 1700 g for 5 
min; subsequently, under sterile conditions and closed form, 
the platelet-rich plasma layer was obtained.
Application of stem cells with autologous platelet growth 
factors. Once ready, the cells were injected in the next two hours 
into the affected joint, by the orthopedist; no premedication was 
used and no other substances were added to the injection. This 
procedure requires a 72-hour disability at home, during which 
time the patient was closely monitored by the health team. An 
indication was given not to consume NSAIDs for up to one 
week after the procedure; if post-infiltration pain treatment 
was required, the use of acetaminophen was indicated. A 
formal rehabilitation program was not recommended.
Between the sixth and the tenth month after infiltration, a 
new magnetic resonance was requested, and the medical team 
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performed the clinical evaluation of the patient (WOMAC scale and the WHOQoL-BREF) and the second arthroscopic 
view, with a final biopsy. The radiologists and pathologists who interpreted the images and biopsies were blinded with 
respect to the doses of applied stem cells.
Magnetic resonances. They were practiced and read by the radiologist without special guidelines, as if they were typical 
patients of medical practice. Therefore, comparisons of the pre- and post-operative charts were made only by classifying 
the type of patella and measuring the thickness of the patellar cartilage at the level of the internal and external facets.
Arthroscopy. Three doctors from the surgical team of the group separately rated the response of the cartilage in the 
area of  greatest commitment, as “very positive” (important changes in the entire cartilage, with good integration to the 
adjacent normal joint surface and normal appearance), “positive” (new cartilaginous tissue is found, partially covering the 
degenerated cartilage), “neutral” (the changes are uncertain) or “negative” (there was progression in the degeneration of 
the cartilage) (23). If there were discrepancies between the evaluators, the decision was adopted by majority.
Biopsies. They were taken during the arthroscopic procedures, before and after the application of the stem cells, in areas 
that the orthopedist considered representative of the local histopathological condition. The plates were analyzed by two 
medical histopathologists.
Finally, the costs of each of the two treatment branches were established, with the purpose of implementing the treatment 
protocol with the best benefit / safety / cost ratio of moderate to severe osteoarthritis of the knee.
Statistics. Due to the small size of the sample non-parametric tests were used in all evaluations. For the differences 
between the two treatment groups, the Mann-Whitney test was used for continuous variables. Changes in quantitative 
variables were evaluated with the Wilcoxon rank test; the qualitative variables were evaluated by Fisher’s test.
Results
Table 1. Demographic and comorbidity characteristics of patients classified according  
to the doses of prescribed stem cells.
CHARACTERISTIC                                                            DOSE OF STEM CELLS         P1
                                                              10 millions                 30 millions   
Age (years)                                       65±17                      63±10                        
BMI2                                                   28±7,4                    26±2,5                        
Time evolution (years)                       4±1,8                      8±7,8                        
Overweight/obesity (n)                          3                             2
Degree of OA (n)
                    II                                        1                             1
                    III                                       4                             4
WOMAC                                             67±14                     52±22
Cartilogram
 Patella internal facet (mm)                2,5±2,0                  2,7±0,9
 Patella external facet (mm)               2,6±2,0                  3,0±1,9
 
1: none of the differences is significant. 
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Table 2. Results of the WOMAC scale.
PATIENT                                                INITIAL WOMAC       FINAL WOMAC         P1
STEM CELLS DOSE                               
Ten millions of stem cells
                  1                                                   46,88                        21,88 
                  2                                                   80,21                        46,35 
                  3                                                   67,71                        58,33 
                  4                                                   59,38                        54,69 
                  5                                                   81,25                        32,29 
Thirty millions of stem cells
                  6                                                 68,75                         46,88 
                  7                                                 37,50                         34,90 
                  8                                                 55,21                         29,69 
                  9                                                 75,00                         37,50 
                 10                                                20,83                         10,42 
 
1: the differences are significant (Wilcoxon test, P=0.005).
Nine women and one man participated in the study, with an average age of 64±13 years (range 40 to 82 years of age), all of 
them received comedication and their predominant comorbidity was hypertension (n=6) and overweight/obesity (n=5). 
The evolution time of osteoarthritis was 5,9±5,7 years (range of 1,0 to 20 years). The data of the baseline conditions of the 
patients are shown in table 1. Table 2 shows the WOMAC scale scores for each of the patients, before and 10 months after the 
application of the stem cells. In the complete group of 10 patients the scores decreased significantly from 59±20 to 37±15 points 
(P=0,005), which is equivalent to a reduction of 37% in the total score of the WOMAC scale, with pain being the symptom that 
responded best (reduction of 41%), followed by functional disability (36,5%) and rigidity (28,6%). There were no differences 
in the WOMAC scale between the two treatment groups (10 million, reduction of 36% vs 30 million, reduction of 38%). 
Table 3. Results of the WHOQoL-BREF of the World Health Organization.
DOMAIN                                                       INITIAL                          4-6 MONTHS AFTER    P4
Perception of quality of life1                          3.9±0.8                            4.0±0.9                      
Satisfaction with health2                                3.9±0.8                           4.0±0.9                      
Physical health (%, quartile)3                        59±18 (average)           64±20 (average)              
Psychological health (%, quartile)3               73±20 (average)            76±20 (average)              
Social relationships (%, quartile)3                 83±11 (high)                  86±8 (high)                
Environnemental conditions (%, quartile)3   73±16 (average)             76±15 (average)             
1: scale from 1 (very bad) to 5 (very good). 
2: scale from 1 (very dissatisfied) to 5 (very satisfied). 
3: scale from 1 to 100, with a degree of satisfaction low (below the first quartile), medium (between the first and third quartile) and 
high (above the third quartile). 
4: none of the differences is significant.
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There were no changes in the perception of quality of life according to the WHOQoL-BREF of the World Health Organization, 
applied to the study entry and between 6 and 10 months after the administration of the stem cells (table 3); no changes were found 
within each treatment subgroup (data not shown).
Fig 1A                                                      Fig 1B    
Figure 1. Arthroscopic knee photographs, taken before (A)and after (B)  stem cells aplication.  (A): lateral knee condyle arthroscopy; 
a denuded area is seen without joint cartilage. (B): arthroscopy of the same knee, in which articular cartilage regeneration is 
appreciated, good integration to the adjacent articular surface and normal appearance.
Arthroscopies (figures 1A and 1B). On the second look, about 10 months after the treatment, the following is the evaluation of the 
arthroscopic results, by the three doctors of the surgical team: result “good/very good” 7 patients, result “neutral” 1 patient, there 
were no negative results and 2 patients did not undergo control arthroscopy, although they reported clinical improvement.
Magnetic resonances. There were no significant differences in the thickness of the patellar cartilage, at the level of 
the internal and external facets, in the cartilages taken at baseline and on average 7.4 months after the application of the 
stem cells (range 6 to 9 months); there were also no differences between patients who received 10 or 30 million cells. 
Fig 2A Fig 2B
 
Figure 2. Microphotographs of osteoarticular knee tissue biopsies taken before (A) and after (B) stem cells aplication (100X 
magnification, hematoxylin/eosin stain). (A) trabecular bone tissue, areas of dense irregular connective tissue, adipose tissue 
(yellow bone marrow) and a sparse area of hyaline cartilage with chondrocytes cells and less affinity for hematoxylin (poor 
basophilia); sparse and eosinophilic territorial matrix;  eosinophilic inter-territorial matrix (B): hyaline cartilage with chondroblasts 
and chondrocytes cells, abundant territorial matrix, with good hematoxylin affinity (marked basophil); different isogenic 
groups of different sizes are observed.
Biopsies. As illustrated in figure 2A, in the plates taken before the application of the stem cells the typical pattern of chondral 
degeneration prevails, while the images of the biopsies taken 10 months later (figure 2B) show unequivocal signs of regeneration, 
with hyaline cartilage, chondroblasts and isogenic groups of different sizes.
Security and adverse events. There were no serious adverse events. The only undesirable symptoms reported by all patients were 
pain and mild-moderate edema in the intervened knee, which were treated ambulatory with rest, local cold and acetaminophen, 
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lasted a few days and resolved without sequelae. 
Costs. The protocol with 10 million stem cells has the same 
effectiveness and safety as the 30 million, but it is logistically 
more convenient, requires less time, and is simpler and cheaper.
Discussion
OA is pathology of high prevalence, which exposes the patient 
to a life with pain and functional limitation, and with serious 
social, labor and economic consequences. The therapeutic 
alternatives based on medications and physiotherapy have 
modest results and do not modify the natural course of the 
disease, so that for many patients, joint replacement ends up 
being their only option. In these circumstances, the search for 
innovative therapies that overcome the precarious results of 
current treatments at affordable costs is justified (24).
The intra-articular application of stem cells and growth 
factors emerges as a promising option, since it is the only 
known alternative with regenerative properties of cartilage 
and other tissues involved in OA. This is indicated by the 
numerous reports of successful results, in which it is shown 
that regenerative medicine is safe, reduces pain and improves 
joint function (8).
However, there are also reports of lack of benefit, which has 
led some authors to consider that the evidence of effectiveness 
is still limited (25). Among the factors that have probably 
influenced the results of the clinical trials some have not been 
consistent, have been the heterogeneity of the studies in terms 
of the type and quality of the stem cells used, its support or 
not with growth factors, the route of administration and the 
amounts applied.
With the purpose of contributing to the clarification of some 
doubts that still persist, in this pilot study we decided to 
look for a type and a dose of stem cells that would meet the 
safety, effectiveness and cost profile, which would allow us to 
propose a protocol for the treatment of OA of knee, based on 
regenerative medicine.
The most remarkable finding of this research is that the intra-
articular application of autologous ADSCs was safe and 
significantly beneficial in patients with knee OA. Apart from 
slight pain and inflammation, there were no significant adverse 
events that could be associated with surgical procedures 
(liposuction and intra-articular injection), or the action of 
stem cells and growth factors. On the other hand, the clinical 
benefit judged by the significant changes in the WOMAC scale 
(table 3) is confirmed by arthroscopic evaluations, which show 
significant growth of the articular cartilage (figures 1A and 
1B), and with the histological findings that show regeneration 
tissue (figures 2A and 2B). It is known that washing and 
debridement performed by the surgeon during arthroscopy 
causes some clinical improvement, but this is temporary and is 
not associated with tissue regeneration (26,27); for this reason, 
the benefit of the patients is attributed to the regenerative 
treatment applied. 
Although the comparison with previous studies is difficult 
due to large differences between them, these results coincide 
with dozens of clinical trials, systematic reviews and meta-
analyzes, in which the effectiveness and safety of the stem 
cells and the growth factors for the treatment of knee OA is 
confirmed (15,17). It should be noted that, although it has 
been demonstrated on different occasions that the age and 
comorbidity of the donor negatively impact the vitality of 
their stem cells (28), our results coincide with other studies 
done with ADSC, in which they do not find a correlation 
between the capacity for differentiation chondrogenic of said 
cells and the age and comorbidity of the donor (12).On the 
other hand, the follow-up time of the patients in our study 
is relatively short, but it should be mentioned that in similar 
cases benefits have been reported in follow-ups of 2 to 5 years 
after the application of stem cells; Even in some studies, the 
improvement in the WOMAC scale has become significant at 
a longer time (2 years), which suggests that our patients could 
continue to improve over time (4,17).
The second result of interest is that no differences were found, 
in terms of safety and effectiveness, between those who 
received 10 or 30 million stem cells, although this finding 
should be taken with caution, because the size of our sample 
was small and the cutting of the evaluation relatively short.
However, the differences between the two doses are clinically 
relevant, since in order to obtain 30 million ADSCs it is 
necessary to expand them ex vivo, with everything that 
involves the cultivation in costs, handling and processing time, 
risk of contamination or change of properties in biological 
cells (29). To have 10 million cells, on the other hand, the 
entire procedure (obtaining fat tissue, isolation of cells and 
intra-articular application) can be done in a single session, 
which takes around two hours. Even so, the autologous 
application requires a previous intervention of liposuction to 
obtain the cells, hence the supply of stem cells is migrating 
towards allogenic sources (for example, umbilical cord), 
which seem to have a similar safety profile to autologous ones, 
with the advantage that can be produced in a standardized way, 
conserved to scale and dispensed in a timely manner, which 
reduces product variability and costs (1,31).
The lack of changes in the quality of life qualification of our 
patients is not surprising, since the WHOQoL-BREF and 
other questionnaires, such as the SF-36 and the SF-18, that 
make a multidimensional assessment of the quality of life 
(area physical, psychological, social and environmental), 
applied in patients with osteoarthritis subjected to different 
treatments, give questionable results or only valid for some 
domains of the questionnaire (13,31). The explanation seems 
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to be that these patients often suffer from other chronic 
diseases, are polymedicated, have psychosocial deprivation 
and difficulties in accessing health services, which are not 
related to joint dysfunction and pain, and are not affected 
during the regenerative treatment (30). For these reasons, 
the questionnaires focused on the particular conditions of the 
patient with OA, such as the WOMAC, which was developed 
specifically for patients with lower limb joint damage, has 
become more reliable and has become a valuable tool in the 
evaluation of functional level and of pain in the patient with 
knee OA (31).
The fact that no differences were found in the magnetic 
resonances made before and after the application of the 
stem cells may be due to the fact that only two anatomical 
points of the patella were measured and compared since the 
average follow-up time was only 7,4 months. Although in 
this short follow-up period there was no additional chondral 
degeneration, most studies that report significant improvements 
in the magnetic resonances show that the responses are not 
uniform at all the points measured, using image qualification 
criteria that include different structures of the knee (such as 
the WORMS or 2D MOCART scales), or have longer follow-
up periods (4,13,23,31). This result allows us to question the 
value of the magnetic resonances that are made in conventional 
clinical practice, for the diagnosis and monitoring of knee 
osteoarthritis.
It is necessary to highlight some limitations of this study. First, 
the size of the sample limits the power of the investigation; 
indeed, large controlled studies are required to get more 
conclusive data on the benefits, not only clinical but structural 
cartilage. Second, the observation period was short to draw 
more definitive conclusions, so it would be desirable to have 
longer-term information, although in any case the response 
of the patients was significant enough to overcome any other 
treatment they received to date. Third, the debridement that is 
made during arthroscopy and the simultaneous use of platelet-
rich plasma will not allow to specify the role of ADSCs in the 
benefit of the patient. Fourth, one fifth of our patients (2/10) did 
not accept control arthroscopy, although with the remaining 
eight patients we demonstrated that there is a correspondence 
between clinical improvement and arthroscopic improvement. 
Finally, some data comes from what was declared by the 
patient, with the consequent reservations of credibility.
The purpose of this pilot study has been to contribute to 
establishing a dose of stem cells with a good benefit / risk 
/ cost ratio, as a contribution to medical practice and to the 
design of randomized and controlled clinical trials, with 
greater evidence power.
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